Anne Chiang, MD

Clinical trials in small cell lung cancer appear to be more “pragmatic” with their inclusion criteria than before, according to Anne Chiang, MD, PhD.

CAR T-cell therapies or other agents that affect the immune system in the long term may be important to keep in mind for the management of SCLC.

Employing patient-reported outcomes may help include those with small cell lung cancer in the shared decision-making process.

In the SWOG S2409 PRISM trial, over 800 patients with small cell lung cancer will receive different treatment regimens based on their disease subtype.

Judy concludes the event and presents the awards.

A debate presented on liquid biopsy versus tissue biopsy to determine front line therapy in metastatic NSCLC.

Dr. Florez leads the discussion on the association between Medicaid insurance, biomarker testing, and the outcomes in patients with advanced NSCLC.

Dr. Herbst discusses the CHRYSALIS Phase 1 trial.

An overview of results from the phase III randomized ADAURA Trial.

A review of Brigatinib versus crizotinib in ALK inhibitor-naïve advanced ALK-positive NSCLC.

A review of adagrasib in the KRYSTAL-1 trial in patients with NSCLC.

A discussion on the Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients with ALK Positive Advanced NSCLC: Phase III CROWN Study

The outcomes of the use of Sotorasib in patients with pretreated KRAS G12C mutated NSCLC.

Highlight on the debate format, speakers, and direction to support the discussion.